Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer
Menée à partir des données d'un essai américain incluant 142 034 participants (durée moyenne de suivi : 9 ans), cette étude évalue l'association entre la consommation régulière d'aspirine ou d'ibuprofène et le risque de cancer de la tête et du cou
Background : Evidence for non-steroidal anti-inflammatory drugs (NSAIDs) preventing head and neck cancer (HNC) is inconclusive; however, there is some suggestion that aspirin may exert a protective effect. Methods : Using data from the United States National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we examined the association between aspirin and ibuprofen use and HNC. Results : Regular aspirin use was associated with a significant 22% reduction in HNC risk. No association was observed with regular ibuprofen use. Conclusion : Aspirin may have potential as a chemopreventive agent for HNC, but further investigation is warranted.